Eli Lilly to invest KRW22bn in ABL Bio.

Eli Lilly, a pharmaceutical company, agreed to invest KRW22bn in ABL Bio, a pharmaceutical company. “We are very pleased to secure a strategic equity investment following our license agreement with Lilly, a global leader in innovative drug development. ABL Bio plans to expand the indications of its Grabody Platform into areas of high unmet medical need, such as obesity and muscle diseases. We expect that this collaboration with Lilly will serve as an important milestone in delivering innovative treatment options to patients worldwide,” Sang Hoon Lee, ABL Bio CEO.